Nexalin Technology, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nexalin Technology, Inc. (NXL) designs and develops non-invasive neurostimulation devices for treating mental health disorders including anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, chronic pain, Alzheimer's disease and dementia; its core products comprise Generation 1, a bioelectronic medical device for anxiety, insomnia and depression without drugs or psychotherapy, Generation 2 SYNC neurostimulation console and Generation 3 HALO Clarity headset utilizing proprietary waveforms to restore brain rhythms. Founded in 2010 and headquartered in Houston, Texas, the company operates primarily in the United States and China with recent international expansion. In November 2025, Nexalin appointed Carmi Masha Technologies Ltd. as exclusive distributor in Israel following regulatory approval for its Gen-2 SYNC 15 mA device; the company also completed an FDA Q-Submission meeting for the Gen-2 SYNC in its Alzheimer's program and received a U.S. patent for neurostimulation technology in September 2025.
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
Critical Analysis: Algorhythm (NASDAQ:RIME) versus Nexalin Technology (NASDAQ:NXL)
Nexalin Technology, Inc. (NASDAQ:NXL) Short Interest Update
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care
EXCLUSIVE: Nexalin Launches AI-Powered Virtual Clinic For Brain Health For Home Settings
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Nexalin Technology (NASDAQ:NXL) Trading 1% Higher – Time to Buy?
Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
Nexalin Technology (NASDAQ:NXL) Shares Down 10.9% – Time to Sell?
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4
Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity